combination glp 1 and sglt2 Influence of therapy with inhibitors GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes A retrospective analysis of combination

Drucker D

2830 In addition to its glucose- and weight-lowering efficacy, semaglutide, when used as add-on standard care in patients with T2DM and high cardiovascular disease, was found to be associated with significantly lower risk of cardiovascular death, nonfatal myocardial infarction, stroke and new or worsening nephropathy compared to placebo

Sanjay Bharti, MD , patients receive a comprehensive evaluation to ensure GLP-1 therapy is safely integrated into a personalized wellness plan

Parents allege that prescribing physicians and drug companies failed to adequately warn about the increased risk of gastrointestinal disorders, prolonged vomiting, and other serious health complications in younger patients

Appetite and Craving Control By mimicking GLP-1, Semaglutide helps patients feel satisfied with smaller portions and reduces food noise and emotional eating

JCI Insight (2018) 3(23):115